Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saline placebo refers to the inactive control treatment used in the CALBLOC clinical trial (NCT05027048) sponsored by Stanford University. This Phase 3, randomized, double-blind trial investigates the use of intravenous calcium chloride to prevent uterine atony and postpartum hemorrhage (PPH) during intrapartum cesarean delivery. The saline placebo is administered as an intravenous infusion to the control group to provide a baseline for comparing the efficacy and safety of calcium chloride in reducing quantitative blood loss and improving uterine tone in high-risk patients. As a placebo, it contains no active pharmacological ingredients and is used to maintain the blinding of the study, allowing researchers to isolate the therapeutic effects of calcium chloride from the effects of the infusion process itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saline placebo.